AMJ Australasian Medical Journal [AMJ 2024;17(2):1166-1173]

AI Machine Learning Improves Personalized Cancer Therapies

Nemat Khansari*

Department of Immunology, Tehran University Medical Sciences, School of Medicine, Iran

Review

Please cite this paper as: Khansari N. AI Machine Learning Improves Personalized Cancer Therapies. AMJ 2024;17(2):1166-1173.

https://doi.org/10.21767/AMJ.2024.4019

Corresponding Author:

Nemat Khansari

Department of Immunology

Tehran University Medical Sciences, School of Medicine

Iran

Email id: nkhansari928@gmail.com

Abstract

Cancer is a complex and heterogeneous disease that challenges healthcare professionals with its unpredictable behavior and resistance to treatment. Currently, personalized cancer treatment is getting more attention for its efficiency as a remedy for patients. Artificial intelligence (AI) has the potential to revolutionize personalized medicine by enabling more accurate and efficient diagnoses, treatment selection, and disease prediction, for instance, cancer, diabetes, and many genetic defects. AI algorithms can analyze large amounts of patient data, including genomic data, medical history, and lifestyle factors, to identify patterns and predict disease risk, treatment effectiveness, and potential adverse reactions. AI can also support the development of personalized treatment plans based on the unique characteristics of each patient, such as their genetic makeup, disease stage, and health history. This approach, known as precision medicine, can significantly improve patient outcomes and reduce healthcare costs by focusing on the most effective treatments for each individual. Moreover, AI-powered tools can help clinicians identify patients at high risk of developing a particular disease and intervene early to prevent or delay its onset. This can be particularly crucial for chronic diseases like diabetes and heart disease, which can be managed more effectively with early intervention.

Furthermore, AI can significantly improve research efficiency and outcomes in personalized medicine by enhancing patient stratification during clinical trials. By leveraging AI-driven algorithms, researchers can identify and group patients based on various factors, such as genetic profiles, disease characteristics, and treatment responsiveness. It should be noted that the impact of AI on personalized medicine is still being explored, and there are many opportunities for this technology to transform healthcare in the coming years. However, it is crucial to ensure that AI is used ethically and responsibly to respect patient privacy and guarantee the accuracy and reliability of the data being analyzed. This review article explores how artificial intelligence can improve prognosis and personalized cancer immunotherapies.

Key Words: Artificial Intelligence, Machine learning, Cancer, Personalized therapy, Immunotherapy.

Early detection and diagnosis are crucial in improving cancer survival rates and reducing the need for aggressive treatments. Machine learning algorithms can analyze medical images, such as mammograms, CT scans, or MRIs, to detect cancer at its earliest stages. These algorithms can identify subtle patterns or abnormalities that may be missed by the human eye, leading to earlier and more accurate diagnoses. Furthermore, machine learning models can analyze patients' clinical and molecular data to predict the likelihood of cancer recurrence, metastasis, or response to treatment. This information helps oncologists develop personalized treatment plans and make more informed decisions about pursuing aggressive therapies, such as chemotherapy or radiation, or opting for more conservative management[1].

Prognosis refers to predicting a disease's likely course and outcome. In cancer treatment, an accurate prognosis enables healthcare professionals to tailor treatment plans and make better- informed decisions. Machine learning algorithms can analyze vast amounts of data from various sources, such as clinical records, genomic profiles, and imaging data, to identify complex patterns and correlations humans can discern [2].

Machine Learning in Personalized Cancer Therapies

Personalized cancer therapies aim to tailor treatment plans based on the unique characteristics of a patient's tumor and genetic makeup. Machine learning is accelerating the development and implementation of personalized cancer therapies in several ways[3].

Identifying Molecular Targets

Cancer cells often have specific genetic mutations or molecular markers distinguishing them from healthy cells. Machine learning algorithms can analyze genomic data to determine these unique targets, which targeted therapies can exploit. By honing in on the specific vulnerabilities of cancer cells, targeted therapies have the potential to be more effective and cause fewer side effects compared to traditional treatments.

Drug Discovery and Development

Developing new cancer drugs is time-consuming and expensive. Machine learning can streamline drug discovery by predicting which compounds are most likely effective against specific cancer types or molecular targets. This accelerates the development process and increases the chances of finding successful treatments.

Treatment Optimization

Machine learning models can predict how patients respond to treatments based on their genetic, clinical, and demographic data. This information enables oncologists to select the most effective treatment options for each patient, improving outcomes and reducing the risk of adverse effects.

Integrating Machine Learning with Immunotherapy Approaches

Immunotherapy is a promising cancer treatment strategy that harnesses the body's immune system to target and eliminate cancer cells. Machine learning can enhance immunotherapy approaches by identifying patients most likely to benefit from these treatments, predicting response rates, and discovering novel immunotherapeutic targets. Not all patients respond equally to immunotherapy treatments; identifying those most likely to benefit is crucial for optimizing outcomes. Machine learning algorithms can analyze clinical, genomic, and immunological data to predict which patients respond best to specific immunotherapies. This personalized approach enables healthcare professionals to make informed decisions about treatment strategies and reduces unnecessary exposure to potentially toxic therapies for non- responders. Machine learning models can help predict how well a patient will respond to a particular immunotherapy treatment by analyzing their tumor microenvironment, genetic mutations, and immune cell infiltration patterns. These predictions provide information for oncologists when deciding on the appropriate course of action and adjusting treatment plans as needed[4].

Immunotherapies often target specific molecules or pathways involved in the immune response against cancer cells. Machine learning can analyze large genomic and proteomic data datasets from tumors and healthy tissues, revealing previously undiscovered targets for immunotherapeutic interventions. By identifying new potential targets, machine learning accelerates the development of innovative immunotherapies that may improve patient outcomes.

Integrating machine learning with immunotherapy approaches can revolutionize cancer care by improving patient selection, predicting response rates, and uncovering novel therapeutic targets. This synergy between cutting-edge technologies paves the way for more effective and personalized cancer treatments that ultimately enhance patient survival rates and quality of life.

Clinical trials are essential for evaluating the safety and efficacy of new cancer treatments. However, patient heterogeneity often leads to varying treatment outcomes, making it difficult to determine the actual effectiveness of a therapy. Machine learning can enhance patient stratification in clinical trials by identifying subgroups of patients with similar characteristics, leading to more accurate results and faster approval of effective therapies. Patient dropout or non-adherence during clinical trials can hinder the evaluation process and delay the development of promising treatments[5]. Machine learning models can predict which patients will most likely adhere to the trial protocol based on their demographic information, medical history, and other factors. This information allows researchers to select more likely participants to complete the trial, reducing attrition rates and increasing the reliability of trial outcomes. Moreover, machine learning algorithms can analyze complex data from multiple sources, such as genomic profiles, proteomic data, and clinical records, to identify distinct patient subgroups. By stratifying patients based on their molecular signatures or disease characteristics, researchers can better understand how different groups respond to a particular treatment and identify potential biomarkers that predict response.

Recruiting suitable participants for clinical trials is often time-consuming and challenging. Machine learning algorithms can rapidly screen large databases of patient records to identify individuals who meet specific eligibility criteria for a given study. This accelerates patient recruitment and ensures trial participants have similar disease characteristics or genetic backgrounds, leading to more reliable results.

By enhancing patient stratification in clinical trials using machine learning algorithms, researchers can obtain more accurate insights into treatment efficacy across various subpopulations. This ultimately accelerates drug development timelines and brings personalized cancer therapies closer to reality for needy patients[6].

Personalizing Dose Distribution Based on Tumor Characteristics

Machine learning models can optimize dose distribution by considering tumor size, shape, location, and surrounding healthy tissues. By tailoring the radiation dose based on these characteristics, machine learning ensures that the optimal amount of radiation is delivered to the target area while minimizing exposure to nearby healthy structures. This personalized approach enhances the therapeutic efficacy of radiation therapy while reducing potential side effects[7].

Adaptive radiation therapy involves adjusting treatment plans based on changes in tumor size or position during treatment. Machine learning techniques can monitor these changes through real- time analysis of imaging data and automatically update treatment plans accordingly. By adapting radiation therapy in response to evolving tumor dynamics, machine learning minimizes damage to healthy tissues while maintaining effective cancer control[8].

Machine learning applications can improve radiation therapy delivery quality by analyzing treatment parameters and identifying potential errors or deviations from planned protocols. These automated checks ensure that discrepancies are promptly detected and corrected before impacting patient outcomes. Integrating machine learning into quality assurance processes enhances safety and accuracy throughout the radiation therapy workflow [9].

By optimizing radiation therapy planning and delivery using machine learning, healthcare professionals can enhance personalized care by improving treatment precision while minimizing damage to healthy tissues. Integrating advanced algorithms in radiation therapy contributes to more accurate and efficient cancer treatment, ultimately leading to better patient outcomes [10].

Machine Learning in Cancer Prevention and Risk Assessment

Cancer prevention and risk assessment are vital in reducing cancer incidence and improving public health. Machine learning can enhance these efforts by identifying high-risk individuals, uncovering modifiable lifestyle factors, and predicting the impact of preventive interventions. Machine learning models can analyze vast amounts of data from various sources, such as genetic information, family history, and environmental factors, to identify individuals at a higher risk of developing cancer. By pinpointing those with an elevated risk, healthcare professionals can implement targeted screening programs or recommend preventive measures to reduce the likelihood of cancer development [11].

Lifestyle factors such as diet, physical activity, and exposure to harmful substances significantly influence an individual's risk of developing cancer. Machine learning algorithms can sift through large datasets to discover patterns between specific behaviors, environmental exposures, and cancer incidence. These insights enable public health authorities to develop evidence-based strategies for promoting healthier lifestyles and reducing exposure to carcinogenic substances.

Evaluating the effectiveness of preventive interventions is crucial for optimizing resource allocation in public health campaigns. Machine learning models can predict the impact of various interventions on population-level cancer incidence by simulating different scenarios based on demographic data, intervention uptake rates, and changes in risk profiles. This information helps policymakers decide which strategies will most likely yield significant reductions in cancer cases while considering cost-effectiveness.

Applying machine learning in cancer prevention and risk assessment can revolutionize early detection efforts, promote healthier lifestyles, and optimize public health initiatives. By harnessing the power of machine learning algorithms to analyze complex data patterns, we can develop more effective strategies for preventing cancer occurrence and ultimately improve population-level health outcomes [12].

Unravelling the Tumor Microenvironment with Machine Learning

The tumor microenvironment (TME) is a complex network of cancer cells, immune cells, blood vessels, and extracellular matrix components that interact dynamically to support tumor growth and metastasis. Understanding the intricate interplay within the TME is crucial for developing effective cancer therapies. Machine learning can be instrumental in decoding the TME's complexity by analyzing multidimensional data from various sources [13].

Machine learning algorithms can process large quantities of single-cell RNA sequencing data to reveal distinct cell populations within the TME and their gene expression profiles. This information helps researchers understand how different cell types communicate with each other and influence tumor behavior. By identifying critical cellular interactions, machine learning can guide the development of therapies that target specific pathways or disrupt essential communication networks within the TME. The infiltration of immune cells into tumors plays a significant role in determining treatment response and patient outcomes. Machine learning models can analyze histopathological images and spatial transcriptomics data to quantify immune cell infiltration patterns across different tumor regions. This information enables oncologists to predict patient responses to immunotherapies better and adjust treatment strategies accordingly [14].

Hypoxia, or low oxygen levels within tumors, drives angiogenesis – the formation of new blood vessels – which supports tumor growth and metastasis. Machine learning algorithms can analyze imaging data such as MRI or PET scans to identify hypoxic regions within tumors and assess vascular density. These insights help researchers develop targeted therapies to normalize blood vessel formation or exploit hypoxic vulnerabilities in cancer cells.

By employing machine learning to unravel the complexities of the tumor microenvironment, we gain valuable insights into cellular interactions, immune infiltration patterns, and angiogenesis dynamics. This knowledge paves the way for innovative therapeutic strategies targeting specific TME components, ultimately improving cancer treatment outcomes and patient survival rates[15,16].

Enhancing Liquid Biopsy Technologies with Machine Learning

Machine learning is revolutionizing cancer diagnostics and management by contributing to developing advanced liquid biopsy technologies. Cell-free DNA fragments released by tumors into the bloodstream contain genetic information that can be used for early cancer detection. Liquid biopsies are a minimally invasive diagnostic tool that analyzes circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers in bodily fluids, such as blood or urine, to detect cancer. Machine learning can significantly improve the sensitivity and specificity of liquid biopsy technologies, enabling earlier cancer detection and more accurate monitoring of treatment response. Circulating tumor cells are often rare and heterogeneous, making their detection challenging. Machine learning algorithms can process high-resolution imaging data from liquid biopsy samples to accurately identify and classify CTCs based on their morphological features and biomarker expression. By enhancing CTC detection rates, machine learning improves cancer diagnosis and provides valuable information for treatment planning. Liquid biopsies offer a real- time snapshot of tumor evolution during treatment, allowing oncologists to monitor therapy effectiveness and detect emerging resistance mechanisms. Machine learning algorithms can analyze longitudinal liquid biopsy data to track changes in CTC counts, cfDNA profiles, or other biomarkers over time. These insights help healthcare professionals make timely adjustments.

Machine Learning-Driven Radiomic Feature Extraction

Radiomic features are quantitative measures extracted from medical images that can provide insights into tumor heterogeneity, microenvironment, and other characteristics relevant to cancer progression. Radiogenomics explores the relationship between radiomic features and underlying genomic alterations in tumors. Radiomics and radiogenomics are emerging fields that leverage quantitative imaging features and genomic data to improve cancer diagnosis, prognosis, and treatment planning. Machine learning algorithms can efficiently analyze large volumes of imaging data to identify relevant radiomic features associated with specific cancer types or treatment outcomes. In addition, Machine learning models can uncover complex patterns linking imaging biomarkers with particular gene mutations or expression profiles, providing valuable information about a patient's prognosis or likelihood of treatment response. By incorporating radiomic and genomic data into predictive models, healthcare providers can develop more personalized prognostic assessments that guide tailored treatment strategies [17,18].

Exploring the Role of Machine Learning in Cancer-Related Pain Management

Cancer-related pain is a significant burden for many patients, affecting their overall quality of life and posing challenges to healthcare providers. Machine learning can enhance pain management strategies by predicting patient needs, optimizing treatment plans, and facilitating early intervention. Machine learning algorithms can analyze vast amounts of patient data, including demographic information, medical history, genetic profiles, and pain assessment scores, to predict the likelihood and intensity of cancer-related pain for individual patients. Healthcare providers can tailor personalized pain management plans that anticipate each patient's unique needs by identifying those at higher risk for severe or chronic pain. Furthermore, Machine learning models can determine the most practical combination of pharmacological and non-pharmacological interventions for managing cancer-related pain. By considering factors such as drug efficacy, side effects, potential interactions with other medications or treatments, and patient preferences, these algorithms can recommend personalized treatment plans that maximize pain relief while minimizing adverse effects[19].

Early intervention is essential for effectively managing cancer-related pain. Machine learning algorithms can identify subtle changes in patient-reported outcomes or physiological markers that may indicate worsening pain or emerging complications related to treatment. This information enables healthcare providers to adjust pain management strategies proactively and address issues before they escalate. Monitoring the effectiveness of pain management strategies is vital for ensuring optimal patient care. Machine learning models can analyze longitudinal data on patient-reported outcomes or objective pain relief measures to evaluate the success of implemented treatment plans[20]. These insights help oncologists decide whether adjustments are needed or if alternative approaches should be explored.

Enhancing Cost-Effectiveness in Cancer Treatment with Machine Learning

Machine learning can play a crucial role in improving the cost-effectiveness of cancer treatment by streamlining decision-making processes, optimizing resource allocation, and reducing treatment-related complications. This ultimately leads to more efficient healthcare systems and better patient outcomes. Healthcare resources are often limited, and efficient allocation is essential for maximizing patient benefit. Machine learning algorithms can analyze patterns in patient data to identify areas where resources may be underutilized or overextended. These insights help healthcare administrators make informed decisions about resource allocation, ensuring that funds are directed toward the most impactful interventions and services[21].

Cancer treatments often come with side effects and complications that can lead to increased healthcare costs due to hospitalizations or additional interventions. Machine learning models can predict which patients are at higher risk for complications based on their unique characteristics, allowing oncologists to take preventive measures or adjust treatment plans accordingly. Machine learning lowers healthcare expenses while enhancing patient well-being by minimizing treatment-related complications.

By leveraging machine learning-driven decision-making in cancer treatment, healthcare systems can enhance cost-effectiveness without compromising the quality of care. Integrating these advanced algorithms into oncological practice promises improved patient outcomes and greater efficiency in managing limited healthcare resources[22].

Addressing Ethical Concerns and Data Privacy in Machine Learning Applications in Oncology

As machine learning continues to revolutionize cancer prognosis and personalized therapies, it is crucial to address ethical concerns and data privacy issues that may arise from its widespread application. Ensuring responsible use of these technologies requires careful consideration of the following aspects[23].

Informed Consent

Obtaining informed consent is essential when using patient data for machine learning algorithms. Patients should be informed of how their information will be utilized, the potential benefits and risks associated with data sharing, and any measures to protect their privacy. Healthcare providers must ensure that consent processes are transparent and easily understandable.

Data Anonymization and Security

Protecting patient privacy is paramount when handling sensitive medical information. Data anonymization techniques can remove personally identifiable information (PII) from datasets before machine learning algorithms analyze them. Additionally, implementing robust security measures such as encryption, access controls, and secure storage solutions can help mitigate the risk of unauthorized access or data breaches.

Bias and Fairness

Machine learning models trained on biased datasets may inadvertently perpetuate disparities in healthcare outcomes among different population groups. To minimize this risk, researchers must ensure that training data accurately represents diverse populations while also addressing any inherent biases within the data. Moreover, regular evaluation of model performance across various demographic groups can help identify potential issues related to fairness and guide necessary adjustments.

Transparency and Explainability

The complexity of some machine learning algorithms can make it challenging for healthcare professionals to understand how they arrive at specific predictions or recommendations. Developing more transparent models with explainable outputs is vital for fostering trust among clinicians and patients while facilitating informed decision-making. Clear documentation on model development processes, validation methods, and limitations can enhance transparency[24].

Collaborative Oversight

Establishing multidisciplinary teams involving oncologists, data scientists, ethicists, and patient advocates can facilitate collaborative oversight of machine learning applications in oncology. This inclusive approach ensures that diverse perspectives are considered when developing and implementing these technologies, ultimately promoting responsible and ethical use.

By addressing ethical concerns and data privacy issues, the oncology community can harness machine learning's power while ensuring patient trust, safeguarding privacy, and promoting equitable healthcare outcomes for all.

Fostering Collaborative Efforts in Machine Learning Applications for Oncology

The successful integration of machine learning applications in oncology relies on the collaboration between researchers, clinicians, and data scientists. By working together, these experts can develop innovative solutions addressing real-world cancer diagnosis, treatment, and prevention challenges. Creating multidisciplinary teams comprising oncologists, bioinformaticians, data scientists, and other relevant specialists promotes a comprehensive approach to solving complex problems in cancer research. These teams can facilitate effective communication between domain experts and ensure that all aspects of the project are addressed with the necessary expertise. Effective collaboration requires sharing data and resources among researchers, clinicians, and data scientists. Developing shared databases or platforms where authorized users can securely access anonymized patient information enables cross-disciplinary analysis of large datasets. This accelerates the discovery of new insights into cancer biology and contributes to developing novel diagnostic tools and treatments[25].

Organizing joint workshops or conferences focused on machine learning applications in oncology fosters networking opportunities among professionals from different fields. These events provide a platform for exchanging ideas, discussing challenges, presenting research findings, and showcasing cutting-edge technologies with potential applications in cancer care. Promoting educational initiatives encouraging professionals from diverse backgrounds to learn about each other's fields can enhance collaborative efforts. For example, training programs for oncologists interested in machine learning techniques or courses tailored to data scientists focusing on cancer biology can bridge knowledge gaps across disciplines.

By fostering collaborative efforts between researchers, clinicians, and data scientists in advancing machine learning applications for oncology, we can maximize the potential impact of these technologies on patient care. This united approach ensures that innovative solutions are developed based on a deep understanding of clinical needs and technological capabilities while enhancing the effectiveness of cancer diagnosis, treatment, and prevention strategies [26].

Adapting Medical Education Curriculum

Incorporating machine learning concepts into medical education curricula ensures that future oncologists possess the necessary skills and knowledge to utilize these advanced technologies effectively. Medical schools should introduce courses or modules focused on data science, artificial intelligence, and machine learning applications in healthcare, equipping students with a comprehensive understanding of how these tools can enhance cancer diagnosis, treatment planning, and patient management.

Continuing education is vital in keeping practicing oncologists up-to-date with advances in machine-learning applications for cancer care. Healthcare organizations should offer workshops, seminars, or online courses that allow clinicians to deepen their understanding of emerging technologies and learn how to integrate them into their practice. These resources should be tailored to address oncologists' needs and challenges while offering practical guidance on implementing machine learning-driven solutions. The rapid pace of innovation in machine learning necessitates a commitment to lifelong learning among oncologists. Encouraging a growth mind-set through on going professional development opportunities helps healthcare providers remain current with cutting-edge advancements in their field. This commitment to continuous learning enables oncologists to adapt to the evolving landscape of cancer care and deliver the best possible patient outcomes[27].

Assessing machine learning's impact on oncology workforce development and training can help educational institutions and organizations proactively adapt their programs to better prepare future healthcare professionals for this technological revolution. By equipping oncologists with the skills, knowledge, and mindset required for success in this new era, we can ensure that machine-learning applications are optimally integrated into clinical practice for improved patient care and outcomes[28].

Conclusion

Machine learning revolutionizes cancer prognosis and personalized therapies by providing valuable insights into disease progression, identifying molecular targets, and optimizing treatment plans. As machine learning algorithms continue to evolve and improve, their applications in oncology hold great promise for enhancing patient care and outcomes. Integrating machine learning in cancer research and clinical practice can significantly improve early detection, prognosis, and the development of targeted therapies that ultimately save lives and enhance the quality of life for cancer patients. Machine learning models can analyze patient characteristics such as age, sex, comorbidities, lifestyle factors, or genetic predispositions to generate personalized prognostic estimates for unique patient-specific factors. These tailored predictions enable healthcare providers to offer more targeted treatment recommendations based on each patient's risk profile while minimizing potential over- or under-treatment scenarios.

By harnessing machine learning's power in cancer-related pain management, healthcare professionals can develop more precise and targeted interventions that improve patients' quality of life. Integrating advanced algorithms into pain management strategies holds promise for reducing the burden of cancer-related pain and enhancing overall patient well-being.

Machine learning enhances the accuracy of cancer staging and risk stratification processes, and healthcare professionals can develop more precise treatment plans tailored to each patient's specific needs. Integrating advanced algorithms in staging and risk assessment contributes to improved decision-making in cancer care and ultimately leads to better clinical outcomes.

By employing machine learning techniques to explore drug repurposing opportunities in oncology, researchers can accelerate the development of novel cancer treatments by leveraging existing knowledge and resources. Integrating advanced algorithms into drug discovery processes contributes to the more efficient identification of promising therapeutics for patients impacted by various cancer types. Moreover, with machine learning to predict and manage the financial burden associated with cancer treatment, healthcare professionals can adopt a proactive approach to addressing monetary challenges patients face throughout their cancer journey. The integration of advanced algorithms in financial care enables targeted interventions that improve overall economic well-being for cancer patients.

References

1. Noorbakhsh-Sabet N, Zand R, Zhang Y, et al. Artificial intelligence transforms the future of health care. Am J Med. 2019;132(7):795-801.
2. Dong Z, Chau MH, Zhang Y, et al. Low-pass genome sequencing–based detection of absence of heterozygosity: validation in clinical cytogenetics. Genet Med.2021;23(7):1225-33. Doi: https://doi.org/10.1038/s41436-021-01128-7
3. Fitzgerald J, Higgins D, Vargas CM, et al. Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. J Clin Pathol. 2021;74(7):429-34. Doi: https://doi.org/10.1136/jclinpath-2020-207351
4. Khansari N. The impact of artificial intelligence on personalized medicine. Vaccination Res Open J. 2024. 7:1-12.
5. Kundu G, Shetty N, Shetty R, et al. Artificial intelligence–based stratification of demographic, ocular surface high-risk factors in progression of keratoconus. Indian J Ophthalmology. 2023;71(5):1882-8.
6. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021.26:80-93.
7. Chen ZH, Lin L, Wu CF, et al.Artificial intelligence is used to assist cancer diagnosis and treatment in the era of precision medicine. Cancer Commun.2021.41:1100-1115.
8. He J, Baxter SL, Xu J, et al. The practical implementation of artificial intelligence technologies in medicine. Nature medicine. 2019;25(1):30-6. Doi: https://doi.org/10.1038/s41591-018-0307-0
9. Sahiner B, Pezeshk A, Hadjiiski LM, et al. Deep learning in medical imaging and radiation therapy. Med Phys. 2019;46(1):e1-36. Doi: https://doi.org/10.1002/mp.13264
10. Ibragimov B, Xing L. Segmentation of organs-at-risks in head and neck CT images using convolutional neural networks. Med Phys. 2017;44(2):547-57. Doi: https://doi.org/10.1002/mp.12045
11. Waden J. Artificial intelligence and its role in the development of personalized medicine and drug control. Wasit J Comput Math Sci. 2022;1(4):126-33. Doi: https://doi.org/10.31185/wjcm.85
12. Strunga M, Urban R, Surovková J, et al. Artificial intelligence systems assisting in the assessment of the course and retention of orthodontic treatment. InHealthcare 2023;11(5):683). Doi: https://doi.org/10.3390/healthcare11050683
13. Komura D, Ishikawa S. Machine learning methods for histopathological image analysis. Compu Struct.Biotech J. 2018;16:34-42.Doi: https://doi.org/10.1016/j.csbj.2018.01.001
14. Ge P, Wang W, Li L, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomedicine & Pharmacotherapy. 2019;118:109228. Doi: https://doi.org/10.1016/j.biopha.2019.109228
15. Gründner J, Prokosch HU, Stürzl M, et al. Predicting Clinical Outcomes in Colorectal Cancer Using Machine Learning. 2018:101-105.
16. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. Doi: https://doi.org/10.1186/s13045-022-01351-y
17. Tabari A, Chan SM, Omar OM, et al. Role of machine learning in precision oncology: applications in gastrointestinal cancers. Cancers. 2022;15(1):63.Doi: https://doi.org/10.3390/cancers15010063
18. Avanzo M, Wei L. Stancenello J, et al. Machine and deep learning methods for radiometrics. Med. Phys. 2020. 47:185-202.
19. Lustberg T, van Soest J, Gooding M, et al. Clinical evaluation of atlas and deep learning based automatic contouring for lung cancer. Radiother Oncol. 2018;126(2):312-7. Doi: https://doi.org/10.1016/j.radonc.2017.11.012
20. Rashidi P, Edwards DA, Tighe PJ. Primer on machine learning: utilization of large data set analyses to individualize pain management. Current Opinion in Anesthesiology. 2019;32(5):653-60. Doi: 10.1097/ACO.0000000000000779
21. Ilan Y. Improving global healthcare and reducing costs using second-generation artificial intelligence-based digital pills: a market disruptor. Int J Environ. Res Public Health. 2021;18(2):811. Doi: https://doi.org/10.3390/ijerph18020811
22. Piccialli F, Giampaolo F, Prezioso E, et al. Artificial intelligence and healthcare: Forecasting of medical bookings through multi-source time-series fusion. Information Fusion. 2021;74:1-6.
23. Mamalakis M, Dwivedi K, Sharkey M, et al. A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension. Scientific Reports. 2023;13(1):3812.
24. Kundu G, Shetty N, Shetty R, et al. Artificial intelligence–based stratification of demographic, ocular surface high-risk factors in progression of keratoconus. Indian J Ophthalmology. 2023;71(5):1882-8. Doi: 10.4103/IJO.IJO_2651_22
25. Bertsimas D, Wiberg H. Machine learning in oncology: methods, applications, and challenges. JCO clinical cancer informatics. 2020;4.
26. Paranjape K, Schinkel M, Panday RN, et al. Introducing artificial intelligence training in medical education. JMIR medical education. 2019;5(2):e16048. Doi: https://doi.org/10.2196/16048
27. Randhawa GK, Jackson M. The role of artificial intelligence in learning and professional development

for healthcare professionals. InHealthcare management forum 2020; 33(1):19-24). Doi: https://journals.sagepub.com/doi/full/10.1177/0840470419869032

28. Mamalakis M, Dwivedi K, Sharkey M, et al. A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension. Scientific Reports. 2023;13(1):3812. Doi: https://doi.org/10.1038/s41598-023-30503-4

Received: *24-Jan-2024, Manuscript No. AMJ-24-4019;* ***Editor assigned:*** *27-Jan-2024, PreQC No. AMJ-24-4019(PQ);* ***Reviewed:*** *10-Feb-2024, QC No. AMJ-24-4019;* ***Revised:*** *15-Feb-2024, Manuscript No. AMJ-24-4019(R);* ***Published:*** *22-Feb-2024*